BCL2 and acute myeloid leukemia: Similarly, inhibition of BCL2 family proteins with ABT-737 or ABT-199 suppressed the clonogenic potential of de novo NRD AML and relapsed NRI AMLs (Figure 8a), consistent with the established role of BCL2 proteins to support cancer cell survival downstream of RALB.38